ASH 2022 | Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, shares some insights into current immunotherapeutic agents being explored for the treatment of diffuse large B-cell lymphoma (DLBCL). Dr Abramson first highlights the approval of CAR-T cells in the second and third-line settings, and then goes on to mention options for transplant-ineligible patients. To conclude, Dr Abramson comments on how bispecific antibodies, including epcoritamab and glofitamab, are showing promising results and are likely to transform the DLBCL treatment armamentarium. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Seattle Genetics: Research Funding; BMS, AbbVie, Genentech, Epizyme, BeiGene, Kymera, Bluebird Bio, Incyte, Kite Pharma, Genmab, Ono Pharma, Mustang Bio, MorphoSys, Regeneron, Century, AstraZeneca, Lilly, Janssen: Consultancy.
